%0 Journal Article
%T Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trials
%A Revels, Sha’Shonda L.
%A Lee, Jay M.
%J Journal of Thoracic Disease
%D 2018
%B 2018
%9 
%! Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trials
%K 
%X Annually, there are over 200,000 lung cancer diagnoses in the United States (1). Only about 15% of patients are diagnosed with early stage disease (1). The prognosis of those with advanced disease, such as stage IIIB or stage IV, is dismal and less than 5% (1). The standard of care includes platinum based systemic therapy combinations. However, treatments are shifting toward newer targeted and small molecule therapies to improve outcomes among patients with advanced non-small cell lung cancer (NSCLC).
%U https://jtd.amegroups.org/article/view/18878
%V 10
%N 2
%P 617-620
%@ 2077-6624